In the News : The Weight Loss Pill That Could Replace Weekly Injections

There is a question that almost every person starting weight loss injections eventually asks: what happens when I stop? The honest answer, as we explored in our recent rebound effect blog, is that weight tends to return for most people once treatment ends — because these medications work with your hormonal system, and when they stop, so do the signals that were keeping hunger in check.

But a significant piece of clinical news, reported this month by the BBC and backed by research published in Nature Medicine, may be about to change the story. A new daily pill — orforglipron, brand name Foundayo — has shown it can help people maintain their weight loss after stopping weekly injections. It is a development that could reshape how millions of people approach long-term weight loss management in the UK and beyond.

What Is Orforglipron — and What Makes It Different?

Orforglipron is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly — the same pharmaceutical company behind Mounjaro. It works in a similar way to injectable weight loss medicines, mimicking the gut hormone GLP-1 to reduce appetite and promote a feeling of fullness. However, unlike Wegovy and Mounjaro, orforglipron is not a peptide-based molecule, which means it can survive digestion without being broken down — allowing it to be taken as a simple tablet.

The practical implications are considerable. There are no weekly injections to administer, no sharps bins to manage, and crucially, Foundayo can be taken at any time of day without food or water restrictions — a notable advantage over oral semaglutide, which requires a strict morning fasting protocol. For people who experience needle anxiety or simply prefer a more discreet, personal approach to their treatment, this could be genuinely transformative.

What Does the Research Actually Show?

The study making headlines was published in Nature Medicine and funded by Eli Lilly. It focused specifically on a transition scenario: what happens when people who have already been on weight loss injections switch to orforglipron instead of stopping altogether?

The trial included 376 participants in the United States who had been taking GLP-1 injections — either tirzepatide (Mounjaro) or semaglutide (Wegovy) — for more than a year and had achieved meaningful weight reduction. Half were switched to daily orforglipron; half received a placebo. The results were clear-cut.

After 36 weeks, participants taking orforglipron maintained an average weight loss of 7.2% from their original starting weight. Those on placebo, by contrast, regained significant weight, ending with an average loss of just 2.6% — illustrating precisely the kind of rebound effect that concerns both patients and clinicians. The pill was well-tolerated, with side effects broadly similar in nature to those seen with injectable GLP-1 medicines: mostly mild, transient gastrointestinal symptoms.

Separately, a major Phase 3 trial called ATTAIN-1, published in The New England Journal of Medicine, studied orforglipron as a standalone weight loss treatment over 72 weeks in 3,127 adults with obesity. Participants lost an average of 11.2% of their body weight on the 36mg dose, compared with just 2.1% on placebo — a clinically meaningful reduction that places orforglipron firmly alongside existing injectable options in terms of efficacy.

Orforglipron at a Glance: Key Facts for UK Patients

Sources: Eli Lilly / FDA (April 2026); ATTAIN-1 (NEJM); Nature Medicine transition study (2026); MHRA/NICE guidance framework

How Does It Compare to Current UK Options?

For UK patients currently using Mounjaro or Wegovy, it is important to understand where orforglipron sits within the broader landscape. As a treatment in its own right, its results are impressive — but it does not yet match the headline weight loss figures achieved by tirzepatide. What it does offer, however, is a genuinely new dimension to treatment planning: the possibility of a pill-based maintenance strategy that could help protect the results achieved during injection therapy.

Weight Loss Treatment Options: A Comparison

Sources: SURMOUNT-1 (Mounjaro); STEP-1 (Wegovy); ATTAIN-1 (Orforglipron); OASIS-4 (Oral semaglutide); Oxford/BMJ meta-analysis (2026)

What Does This Mean for UK Patients Right Now?

As of May 2026, orforglipron is not yet approved for use in the United Kingdom. The medication received approval from the US Food and Drug Administration in April 2026 under the brand name Foundayo, and Eli Lilly has submitted it for regulatory review in over 40 countries. For the UK, MHRA approval is the first required step, followed by a NICE assessment before NHS commissioning could begin. Industry analysts currently anticipate that private prescribing could become possible from late 2026, with NHS access taking longer.

The oral Wegovy pill (oral semaglutide) — a separate product from Novo Nordisk — is also awaiting a UK decision, with analysts suggesting a possible MHRA approval in mid-2026. Neither product is available through any UK pharmacy yet, and any provider currently claiming to sell orforglipron in the UK is not operating legally or safely. This is precisely the kind of risk that choosing a regulated, GPhC-registered online pharmacy helps you avoid.

Why This Matters: Obesity as a Long-Term Condition

The orforglipron story is about more than one new pill. It reflects a broader and increasingly accepted understanding in UK clinical medicine: that obesity is a chronic, relapsing condition that often requires ongoing, personal and medically supervised management — much like high blood pressure or type 2 diabetes.

The April 2026 NICE guidance recommending Wegovy for patients with cardiovascular disease reinforced this view. Weight loss injections are no longer being positioned purely as cosmetic interventions — they are being recognised as medicines with serious, life-saving health implications. The emergence of orforglipron as a potential transition or maintenance tool fits naturally into this evolving clinical picture.

For patients currently on Mounjaro or Wegovy, this research offers something genuinely valuable: the prospect of a future in which stopping your injection does not have to mean starting over. Instead, a daily pill could help you maintain the results you have achieved, without the commitment to ongoing injections.

What Should You Do If You Are Interested in Orforglipron?

The most important message for UK patients right now is one of informed patience. Orforglipron is not yet available in the UK, and anyone claiming to offer it cannot be trusted to be providing a safe or legal product. When it does become licensed, it will be the kind of development we discuss proactively with our patients at Happy Pharmacy.

In the meantime, there are meaningful steps you can take:

•       Continue your current Mounjaro or Wegovy treatment as prescribed and do not stop without clinical guidance

•       Speak to your Happy Pharmacy prescriber if you are thinking about your long-term treatment plan

•       Focus on embedding the dietary and lifestyle habits that will support your results whatever treatment path you follow

•       Stay informed through trusted, regulated sources — not social media claims or unlicensed providers

•       Register your interest with your pharmacy so you can be updated when orforglipron becomes available in the UK

Blog medically reviewed by : Palvinder Deol, GPhC Registered Pharmacist, 27 May 2026

1. Orforglipron for weight maintenance after GLP-1 injection therapy: a randomised trial. Nature Medicine. 2026.

2. Orforglipron for obesity (ATTAIN-1): a phase 3 randomised controlled trial. New England Journal of Medicine. 2025.

3. BBC News. Daily pill helps keep weight off after stopping obesity jabs. May 2026.

4. NHS England. Over a million people could be offered Wegovy to cut heart attack and stroke risk on the NHS. April 2026.

5. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity. Technology Appraisal TA875. 2023.

6. Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.

7. Eli Lilly. FDA approves Foundayo (orforglipron). April 2026.

8. MHRA. Medicines and Healthcare products Regulatory Agency — licensing medicines in the UK.